Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:607 (24 March), doi:10.1136/bmj.39157.476910.DB
Janice Hopkins Tanne
New York
| The first 150 words of the full text of this article appear below. |
Merck will appeal against the decision that a New Jersey state court jury made on 12 March to award compensatory and punitive damages of $47.5m (£24.4m;
35.7m) to an Idaho man, Frederick Humeston, and his wife Mary, for a heart attack he had in 2001, when he was 56.
The damages, awarded after the retrial of an earlier case that Mr Humeston lost, were $18m to Mr Humeston, $2m to his wife, and $27.5 in punitive damages. The jury decided that Merck was negligent in not warning Mr Humeston of the risk of taking rofecoxib (Vioxx).
Merck voluntarily withdrew rofecoxib, a cyclo-oxygenase-2 inhibitor, from the market on 30 September 2004 because it increased the risk of heart attacks and strokes (BMJ 2005;329:816).
Merck faces more than 27 000 lawsuits related to rofecoxib, including about 120 from the United Kingdom. The company has said it will fight each one and
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?